Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Zinc supplementation for the prevention of type 2 diabetes mellitus

Esta versión no es la más reciente

Información

DOI:
https://doi.org/10.1002/14651858.CD005525Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 19 octubre 2005see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Trastornos metabólicos y endocrinos

Copyright:
  1. Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Vânia Beletate

    Correspondencia a: Programa de graduacao de Medicina Interna e Terapeutica, Universidade Federal de São Paulo, Piracicaba, Brazil

    [email protected]

  • Álvaro N Atallah

    Brazilian Cochrane Centre, Universidade Federal de São Paulo, São Paulo, Brazil

  • Regina P El Dib

    São Paulo, Brazil

Contributions of authors

Vânia Beletate (VB) is responsible for the design, will be responsible for writing to the authors of papers for any additional information and locating potentially relevant unpublished or ongoing studies. She will be responsible for the data management of the review as well as screening the retrieved papers against inclusion criteria, appraising the quality of the papers and extracting the data.

Álvaro Nagib Atallah (ANA) is responsible for co‐ordinating this protocol.

Regina Paolucci El Dib (RPED) will be responsible for the search strategy; running the searches; screening the search results; obtaining papers, screening the retrieved papers against inclusion criteria, appraising the quality of the papers and extracting the data.

VB and RPED will analyse and interpret data and will write up the results.

Declarations of interest

None known.

Acknowledgements

The authors would like to thank Regis Bruni Andriolo for his useful advice in the development of this review.

Version history

Published

Title

Stage

Authors

Version

2015 May 28

Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance

Review

Regina El Dib, Orsi LF Gameiro, Matheus SP Ogata, Norma SP Módolo, Leandro G Braz, Eliane C Jorge, Paulo do Nascimento Junior, Vânia Beletate

https://doi.org/10.1002/14651858.CD005525.pub3

2007 Jan 24

Zinc supplementation for the prevention of type 2 diabetes mellitus

Review

Vânia Beletate, Regina El Dib, Álvaro N Atallah

https://doi.org/10.1002/14651858.CD005525.pub2

2005 Oct 19

Zinc supplementation for the prevention of type 2 diabetes mellitus

Protocol

Vânia Beletate, Álvaro N Atallah, Regina P El Dib

https://doi.org/10.1002/14651858.CD005525

Keywords

MeSH

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Table 1. Table 01 Search Strategy for identification of studies

Database

Search strategy

Unless otherwise stated, search terms were free text terms; exp = exploded MeSH: Medical subject heading (Medline medical index term); the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH: Medical subject heading (Medline medical index term); adj = adjacency.

Medline (OVID)

(1) exp ZINC/
(2) zinc.tw.
(3) 1 or 2
(4) exp diabetes mellitus/
(5) diabet$.tw.
(6) IDDM.tw.
(7) NIDDM.tw.
(8) MODY.tw.
(9) (late onset adj diabet$).tw.
(10) (maturity onset adj diabet$).tw.
(11) (juvenil adj diabet$).tw.
(12) exp Syndrome X/
(13) (syndrome X and diabet$).tw.
(14) hyperinsulin$.tw.
(15) insulin sensitiv$.tw.
(16) insulin$ secret$ dysfunc$.tw.
(17) impaired glucose toleran$.tw.
(18) glucose intoleran$.tw.
(19) exp Glucose Intolerance/
(20) insulin$ resist$.tw.
(21) (non insulin$ depend$ or noninsulin$ depend$ or non insulin?depend$ or noninsulin?depend$).tw.
(22) metabolic$ syndrom$.tw.
(23) (pluri metabolic$ syndrom$ or plurimetabolic$ syndrom$).tw.
(24) ((typ$ 1 or typ$ 2) and diabet$).tw.
(25) ((typ$ I or typ$ II) and diabet$).tw.
(26) exp Insulin Resistance/
(27) (insulin$ depend$ or insulin?depend$).tw.
(28) or/4‐27
(29) limit 28 to human
(30) randomized controlled trial.pt.
(31) controlled clinical trial.pt.
(32) randomized controlled trials.sh.
(33) random allocation.sh.
(34) double‐blind method.sh.
(35) single‐blind method.sh.
(36) or/30‐35
(37) limit 36 to animal
(38) limit 36 to human
(39) 37 not 38
(40) 36 not 39
(41) clinical trial.pt.
(42) exp clinical trials/
(43) (clinic$ adj25 trial$).tw.
(44) ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.
(45) placebos.sh.
(46) placebo$.tw.
(47) random$.tw.
(48) research design.sh.
(49) (latin adj square).tw.
(50) or/41‐49
(51) limit 50 to animal
(52) limit 50 to human
(53) 51 not 52
(54) 50 not 53
(55) comparative study.sh.
(56) exp evaluation studies/
(57) follow‐up studies.sh.
(58) prospective studies.sh.
(59) (control$ or prospectiv$ or volunteer$).tw.
(60) cross‐over studies.sh.
(61) or/55‐ 60
(62) limit 61 to animal
(63) limit 61 to human
(64) 62 not 63
(65) 61 not 64
(66) 40 or 54 or 65
(67) 3 and 29 and 66

Lilacs

#1 = Zinc OR (Serum Zinc Level$) #2 = (Adult‐Onset Diabetes Mellitus) OR (Adult Onset Diabetes Mellitus) OR (Ketosis‐Resistant Diabetes Mellitus) OR (Ketosis Resistant Diabetes Mellitus) OR (Maturity‐Onset Diabetes Mellitus) OR (Maturity Onset Diabetes Mellitus) OR (Non Insulin Dependent Diabetes Mellitus)
OR (Non‐Insulin‐Dependent Diabetes Mellitus) OR (Noninsulin Dependent Diabetes Mellitus) OR (Slow‐Onset Diabetes Mellitus) OR (Slow Onset Diabetes Mellitus) OR (Stable Diabetes Mellitus) OR (Type II Diabetes Mellitus) OR MODY OR NIDDM OR (Type 2 Diabetes Mellitus) OR (insulin resistance) OR Hyperinsulinemia OR (Compensatory Hyperinsulinemia) OR (Endogenous Hyperinsulinism) OR (Exogenous Hyperinsulinism) OR (Glucose Metaboli$ Disorder$) OR (Glucose intolerance$) OR hyperglycemia$ #3 = (Pt randomized controlled trial) OR (Pt controlled clinical trial) OR (Mh randomized controlled trials) OR (Mh random allocation) OR (Mh double blind method) OR (Mh single blind method) AND NOT (Ct animal) AND NOT (Ct human and Ct animal) OR (Pt clinical trial) OR (Ex E05.318.760.535$) OR (Tw clin$) AND (Tw trial$) OR (Tw ensa$) OR (Tw estud$) OR (Tw experim$) OR (Tw investiga$) OR (Tw singl$) OR (Tw simple$) OR (Tw doubl$) OR (Tw doble$) OR (Tw duplo$) OR (Tw trebl$) OR (Tw trip$) AND (Tw blind$) OR (Tw cego$) OR (Tw ciego$) OR (Tw mask$) OR (Tw mascar$) OR (Mh placebos) OR (Tw placebo$) OR (Tw random$) OR (Tw randon$) OR (Tw casual$) OR (Tw acaso$) OR (Tw azar) OR (Tw aleator$) OR (Mh research design) AND NOT (Ct animal) AND NOT (Ct human and Ct animal) OR (Ct comparative study) OR (Ex E05.337$) OR (Mh follow‐up studies) OR (Mh prospective studies) OR (Tw control$) OR (Tw prospectiv$) OR (Tw volunt$) OR (Tw volunteer$) AND NOT ((Ct animal) AND NOT (Ct human and Ct animal))

Figuras y tablas -
Table 1. Table 01 Search Strategy for identification of studies